This article appears to contradict the article
HGH Fragment 176–191. |
Names | |
---|---|
IUPAC name
(2S)-2-[[2-[[(4R,7S,13S,16S,19S,22S,25R)-25-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-22-(3-carbamimidamidopropyl)-13-(2-carboxyethyl)-7,19-bis(hydroxymethyl)-6,9,12,15,18,21,24-heptaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid
| |
Other names
H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH
| |
Identifiers | |
3D model (
JSmol)
|
|
Abbreviations | YLRIVQCRSVEGSCGF |
ChemSpider | |
PubChem
CID
|
|
UNII | |
| |
| |
Properties | |
C78H123N23O23S2 | |
Molar mass | 1815.10 g·mol−1 |
Related compounds | |
Related compounds
|
HGH Fragment 176–191 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
AOD9604 is an orally active, lipolytic peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the C-terminal end. [1] Human trials show that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production. [2]
AOD9604 appears to enhance lipolysis by upregulating beta-3 adrenergic receptors. Beta-3 adrenergic receptor knockout mice are unresponsive to the lipolytic effects of AOD9604. [1]
In a 12 week randomised trial, subjects receiving AOD9604 lost, on average, 1.8kg more than those receiving placebo. [3] Development of AOD9604 was halted following insignificant efficacy in a later 24 week trial. [3]
This article appears to contradict the article
HGH Fragment 176–191. |
Names | |
---|---|
IUPAC name
(2S)-2-[[2-[[(4R,7S,13S,16S,19S,22S,25R)-25-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-22-(3-carbamimidamidopropyl)-13-(2-carboxyethyl)-7,19-bis(hydroxymethyl)-6,9,12,15,18,21,24-heptaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid
| |
Other names
H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH
| |
Identifiers | |
3D model (
JSmol)
|
|
Abbreviations | YLRIVQCRSVEGSCGF |
ChemSpider | |
PubChem
CID
|
|
UNII | |
| |
| |
Properties | |
C78H123N23O23S2 | |
Molar mass | 1815.10 g·mol−1 |
Related compounds | |
Related compounds
|
HGH Fragment 176–191 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
AOD9604 is an orally active, lipolytic peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the C-terminal end. [1] Human trials show that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production. [2]
AOD9604 appears to enhance lipolysis by upregulating beta-3 adrenergic receptors. Beta-3 adrenergic receptor knockout mice are unresponsive to the lipolytic effects of AOD9604. [1]
In a 12 week randomised trial, subjects receiving AOD9604 lost, on average, 1.8kg more than those receiving placebo. [3] Development of AOD9604 was halted following insignificant efficacy in a later 24 week trial. [3]